Stem cell-based technologies are one of the most promising approaches in the further advancement of cell therapy and regenerative medicine. Also, great hopes are linked to using stem cells as a tool for drug discovery. In order to make progress towards commercialization, researchers in the field are evaluating standardization of their cultivation and efficient scale-up.
Controlled Cultivation of Stem Cells - Factors to Consider When Thinking of Scale-Up
Widely established in traditional cell culture, controlled bioreactors have the potential to establish reproducible expansion of stem cells. They provide extensive options for monitoring and control of key parameters such as pH and dissolved oxygen in real-time and facilitate a controlled differentiation of the cells. Through scalable bioreactor design, results obtained in small scale can be transferred to larger working volumes while maintaining optimum mass transfer.
Dr. Nold joined the Eppendorf Bioprocess Center as an Infield Application Specialist for stem cells. In this interview he speaks about the latest advances in bioprocessing.
Main aspect of this interview is: Biopharma know-how meets bioreactor innovation in upstream bioprocessing.
Click here to read the interview
Induced pluripotent stem cells
Since the pioneering development of cell reprogramming by Shinya Yamanaka in 2006, induced pluripotent stem cells (iPSCs) have risen to be the most promising alternative to ethically problematic embryonic stem cells. Controlled cultivation and scale-up in clinical grade as well as ways to control their differentiation towards their final destiny will be key steps towards commercial use of these cells.
generated hiPSC-derived neurospheres for drug research applications. They demonstrated the potential of the DASbox Mini Bioreactor for such a process.
A team of researchers from
developed a bioprocess for the large-scale manufacturing of cardiomyocytes derived from a variety of healthy and diseased hiPSC lines. They expanded hiPSCs as cell aggregates in a DASbox® Mini Bioreactor System and scaled-up the process using a BioFlo 320 bioprocess control system.
Mesenchymal stem cells (MSCs) are multipotent cells derived from the bone marrow, from adipose tissue, cord blood or other tissues related to the embryonic mesoderm. They are relatively easy to obtain and have great potential for cell therapy and drug screening.
Various MSCs have been successfully cultivated in stirred-tank bioreactors.
The Stem Cell Community Day connects researchers from all over the world to review recent advances in the area of stem cells, with a special focus on cultivation in stirred-tank bioreactors.
At our 1st Stem Cell Community Day in April 2017 we brought together experts from industry and academia, to discuss latest achievements, challenges, and chances in stem cell bioprocessing for research and commercial manufacturing.
eBook: Advancing medicine - Can cell and gene therapies paint a picture of perfect future health? (The Medicine Maker, sponsored by Eppendorf) 3.2 MB, PDF